Qlaris Bio Appoints Parisa Zamiri, M.D., Ph.D., to Board of Directors

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Parisa Zamiri, M.D., Ph.D., to its board of directors. Dr. Zamiri's appointment comes as Qlaris continues to advance its lead development program, QLS-111, through late-stage clinical trials as a novel therapeutic agent for the treatment of glaucoma.Dr. Zamiri is a physician-scientist and ophthalmologist by traini